Translated title of the contribution: Dogmatil in tardive dyskinesia

J. Gerlach, Daniel Casey

Research output: Contribution to journalArticle

2 Scopus citations


Delayed dyskinesia (DD) apparently originates in the combination of an individual susceptibility and an antidopaminergic (neuroleptic) treatment. This combination may be responsible for: 1) relative hypersensitivity to dopamine with a rise in the number of dopaminergic receptors and/or depressed cholinergic activity (reversible DD); 2) a degenerative process, in prolonged treatments, resulting in a lowered threshold for emergence of dyskinetic manifestations (irreversible DD). Dogmatil, through selective blockade of D-2 dopaminergic receptors, is capable of reversing DD without exacerbating the parkinson-like syndrome. However, in predisposed patients, parkinson-like manifestations may be induced or exacerbated by dogmatil. Findings in animals suggest that the risk of including DD is less with dogmatil than with conventional neuroleptics. Nevertheless, long term clinical trials are needed to test this hypothesis.

Original languageFrench
Pages (from-to)1369-1375
Number of pages7
JournalSemaine des Hopitaux
Issue number19
Publication statusPublished - 1985
Externally publishedYes


ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gerlach, J., & Casey, D. (1985). LE DOGMATIL DANS LES DYSKINESIES TARDIVES. Semaine des Hopitaux, 61(19), 1369-1375.